NCT06510283View on ClinicalTrials.gov

Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2028

Conditions
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Interventions
DRUG

Taitacept

Telitacicept will be subcutaneously injected at a dose of 240mg per week, lasting for at least 24 weeks.

Trial Locations (1)

100730

RECRUITING

Beijing Tongren Hospital,Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Tongren Hospital

OTHER